Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[TUT-7 phase I clinical study. TUT-7 Study Group]

T Taguchi1, A Wakui, H Niitani

  • 1Research Institute for Microbial Diseases, Osaka University (Japan Society for Cancer Chemotherapy at present).

Gan to Kagaku Ryoho. Cancer & Chemotherapy
|July 1, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Processing of CD109 by furin and its role in the regulation of TGF-beta signaling.

Oncogene·2010
Same author

Responses to 5-HT in morphologically identified neurons in the rat substantia gelatinosa in vitro.

Neuroscience·2009
Same author

Action of neuropeptide Y on nociceptive transmission in substantia gelatinosa of the adult rat spinal dorsal horn.

Neuroscience·2005
Same author

[Anti-nociceptive effect of calcitonin on chronic pain associated with osteoporosis].

Clinical calcium·2005
Same author

Functional reorganization of the spinal pain pathways in developmental and pathological conditions.

Novartis Foundation symposium·2004
Same author

Analysis of receptive fields revealed by in vivo patch-clamp recordings from dorsal horn neurons and in situ intracellular recordings from dorsal root ganglion neurons.

Life sciences·2004

This phase I trial evaluated TUT-7, an anthracycline antibiotic, in 35 cancer patients. The recommended dose for further studies is 100 mg/day orally for 14 days, with low drug accumulation observed.

Area of Science:

  • Pharmacology
  • Oncology
  • Clinical Trials

Background:

  • TUT-7 is a novel anthracycline antitumor antibiotic.
  • Phase I clinical trials are essential for evaluating new cancer therapeutics.

Purpose of the Study:

  • To determine the safety and maximum tolerated dose (MTD) of TUT-7 in cancer patients.
  • To establish a recommended dosing regimen for future clinical studies.

Main Methods:

  • A nationwide phase I study involving 35 patients with malignant tumors.
  • Dose escalation using a modified Fibonacci scheme for single and consecutive day dosing.
  • Monitoring for dose-limiting toxicities, primarily leukopenia.

Main Results:

  • The MTD for single dosing was 700 mg/body.

Related Experiment Videos

  • The MTD for consecutive daily dosing was 100 mg/body/day.
  • Serum drug concentrations plateaued by day 5 with low drug accumulation.

    • Conclusions:

    • TUT-7 demonstrates a favorable safety profile within the tested dose ranges.
    • A regimen of 100 mg/body/day orally for 14 consecutive days is recommended for phase II studies.
    • Low drug accumulation suggests a manageable toxicity profile for sustained treatment.